Goldman Sachs’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-52,328
| Closed | -$28K | – | 6530 |
|
|
2024
Q4 | $28K | Buy |
52,328
+12,251
| +31% | +$8.54K | ﹤0.01% | 5877 |
|
|
2024
Q3 | $70.5K | Sell |
40,077
-542,020
| -93% | -$757K | ﹤0.01% | 5609 |
|
|
2024
Q2 | $681K | Buy |
582,097
+445,780
| +327% | +$1.12M | ﹤0.01% | 4658 |
|
|
2024
Q1 | $1.23M | Buy |
136,317
+63,698
| +88% | +$619K | ﹤0.01% | 4206 |
|
|
2023
Q4 | $789K | Sell |
72,619
-43,582
| -38% | -$327K | ﹤0.01% | 4515 |
|
|
2023
Q3 | $935K | Buy |
116,201
+50,678
| +77% | +$422K | ﹤0.01% | 4312 |
|
|
2023
Q2 | $712K | Sell |
65,523
-88,636
| -57% | -$759K | ﹤0.01% | 4547 |
|
|
2023
Q1 | $1.06M | Buy |
154,159
+90,188
| +141% | +$566K | ﹤0.01% | 4340 |
|
|
2022
Q4 | $255K | Sell |
63,971
-59,048
| -48% | -$290K | ﹤0.01% | 5213 |
|
|
2022
Q3 | $818K | Buy |
123,019
+77,435
| +170% | +$477K | ﹤0.01% | 4652 |
|
|
2022
Q2 | $220K | Sell |
45,584
-111,365
| -71% | -$677K | ﹤0.01% | 5600 |
|
|
2022
Q1 | $1.47M | Buy |
156,949
+5,380
| +4% | +$53.4K | ﹤0.01% | 4513 |
|
|
2021
Q4 | $1.8M | Sell |
151,569
-87,556
| -37% | -$1.01M | ﹤0.01% | 4340 |
|
|
2021
Q3 | $2.72M | Buy |
239,125
+4,253
| +2% | +$58.5K | ﹤0.01% | 3909 |
|
|
2021
Q2 | $4.21M | Buy |
234,872
+4,878
| +2% | +$78.5K | ﹤0.01% | 3491 |
|
|
2021
Q1 | $3.56M | Buy |
229,994
+167,018
| +265% | +$2.42M | ﹤0.01% | 3451 |
|
|
2020
Q4 | $768K | Buy |
62,976
+31,253
| +99% | +$436K | ﹤0.01% | 4367 |
|
|
2020
Q3 | $408K | Sell |
31,723
-64,100
| -67% | -$553K | ﹤0.01% | 4592 |
|
|
2020
Q2 | $974K | Buy |
95,823
+80,950
| +544% | +$745K | ﹤0.01% | 3971 |
|
|
2020
Q1 | $121K | Sell |
14,873
-9,219
| -38% | -$79.9K | ﹤0.01% | 4895 |
|
|
2019
Q4 | $208K | Buy |
24,092
+3,110
| +15% | +$17.5K | ﹤0.01% | 4877 |
|
|
2019
Q3 | $130K | Sell |
20,982
-437,125
| -95% | -$3.53M | ﹤0.01% | 4925 |
|
|
2019
Q2 | $7.61M | Buy |
458,107
+2,853
| +0.6% | +$49.5K | ﹤0.01% | 2564 |
|
|
2019
Q1 | $7.61M | Sell |
455,254
-36,920
| -8% | -$532K | ﹤0.01% | 2647 |
|
|
2018
Q4 | $5.65M | Buy |
492,174
+366,502
| +292% | +$7.42M | ﹤0.01% | 2769 |
|
|
2018
Q3 | $5.03M | Buy |
125,672
+118,567
| +1,669% | +$3.37M | ﹤0.01% | 2987 |
|
|
2018
Q2 | $201K | Sell |
7,105
-29,702
| -81% | -$658K | ﹤0.01% | 4990 |
|
|
2018
Q1 | $562K | Buy |
36,807
+27,471
| +294% | +$654K | ﹤0.01% | 4415 |
|
|
2017
Q4 | $305K | Buy |
+9,336
| New | +$252K | ﹤0.01% | 5168 |
|
|
2016
Q3 | – | Sell |
-3,104
| Closed | -$16K | – | 7230 |
|
|
2016
Q2 | $16K | Buy |
+3,104
| New | +$57.2K | ﹤0.01% | 6778 |
|
|
2015
Q4 | – | Sell |
-19,220
| Closed | -$641K | – | 7387 |
|
|
2015
Q3 | $641K | Sell |
19,220
-7,327
| -28% | -$413K | ﹤0.01% | 4902 |
|
|
2015
Q2 | $1.23M | Buy |
26,547
+22,378
| +537% | +$836K | ﹤0.01% | 4341 |
|
|
2015
Q1 | $150K | Sell |
4,169
-351
| -8% | -$15.4K | ﹤0.01% | 6207 |
|
|
2014
Q4 | $191K | Sell |
4,520
-8,707
| -66% | -$253K | ﹤0.01% | 6191 |
|
|
2014
Q3 | $342K | Buy |
+13,227
| New | +$409K | ﹤0.01% | 5637 |
|
Goldman Sachs's MRNS Position: Q1 2025 in Review
Goldman Sachs sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2025, closing a stake of 52,328 shares — an estimated $28K sold.
Goldman Sachs first reported a position in MRNS in Q3 2014 and held it in 35 quarters. The position peaked at $7.61M in Q1 2019. 0 funds tracked by Wall St. Rank hold MRNS as of Q1 2025.
- Goldman Sachs reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2025 after selling out during the quarter.
- Goldman Sachs sold 52,328 Marinus Pharmaceuticals, Inc shares in Q1 2025, an estimated $28K.
- Goldman Sachs first reported a position in Marinus Pharmaceuticals, Inc in Q3 2014 and held it in 35 quarters.
- Goldman Sachs's Marinus Pharmaceuticals, Inc position peaked at $7.61M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2025.
Based on Goldman Sachs's 13F filing for Q1 2025, filed 9 May 2025.